For research use only. Not for therapeutic Use.
JAK-IN-5 hydrochloride is an inhibitor of JAK extracted from patent US20170121327A1, compound example 283[1].
JAK-IN-5 hydrochloride (compound 1) (oral aspirate, 0.5 mg/mL, 50 μL ) inhibits STAT6 phosphorylation by 60% in IL-13-induced in lung tissue in a mouse model of pSTAT6 induction[2].
JAK-IN-5 hydrochloride (compound 1) (oral aspirate, 0.1-1.0 mg/mL, 50 μL) inhibits 88% of BALF eosinophils in male C57 mice model of Alternaria alternata-induced eosinophilic inflammation of the lung[2].
| Catalog Number | I045878 |
| CAS Number | 2751323-21-2 |
| Synonyms | 5-ethyl-2-fluoro-4-[3-[5-(1-methylpiperidin-4-yl)-3,4,6,7-tetrahydroimidazo[4,5-c]pyridin-2-yl]-1H-indazol-6-yl]phenol;hydrochloride |
| Molecular Formula | C27H32ClFN6O |
| Purity | ≥95% |
| InChI | InChI=1S/C27H31FN6O.ClH/c1-3-16-13-25(35)21(28)14-20(16)17-4-5-19-23(12-17)31-32-26(19)27-29-22-8-11-34(15-24(22)30-27)18-6-9-33(2)10-7-18;/h4-5,12-14,18,35H,3,6-11,15H2,1-2H3,(H,29,30)(H,31,32);1H |
| InChIKey | IQLPCWWFLJIQJF-UHFFFAOYSA-N |
| SMILES | CCC1=CC(=C(C=C1C2=CC3=C(C=C2)C(=NN3)C4=NC5=C(N4)CN(CC5)C6CCN(CC6)C)F)O.Cl |
| Reference | [1]. Paul R. Fatheree, et al. JAK Kinase Inhibitor Compounds for Treatment of Respiratory Disease. US20170121327A1. [2]. Venkat R, et al. Methods of treatment using a jak inhibitor compound. US20180311226. |
